What is the clinical evidence from this study?

Study design: Cohort. Population: Cardiac sarcoidosis (n=19). Intervention: Cardiac resynchronization therapy (CRT) vs. Baseline. Primary outcome: QRS duration at 6 months (p=<0.001).

What does this research mean for the field?

In patients with advanced cardiac sarcoidosis, cardiac resynchronization therapy improves QRS duration and NYHA functional class but fails to induce echocardiographic reverse remodeling, and overall clinical outcomes remain poor. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To assess the efficacy, echocardiographic reverse remodeling, and long-term clinical outcomes of cardiac resynchronization therapy (CRT) in patients with cardiac sarcoidosis.

August 22, 2026Heart and Vessels

Real-world clinical outcomes after cardiac resynchronization therapy in cardiac sarcoidosis

Q: What are the key findings of this study?

Cardiac resynchronization therapy in cardiac sarcoidosis shortened QRS duration (172 to 128 ms, p<0.001) but did not improve LVEF (28% vs 28%, p=0.452) at 6 months.

Q: What does this research mean for the field?

In patients with advanced cardiac sarcoidosis, cardiac resynchronization therapy improves QRS duration and NYHA functional class but fails to induce echocardiographic reverse remodeling, and overall clinical outcomes remain poor. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Q: What question did this study set out to answer?

To assess the efficacy, echocardiographic reverse remodeling, and long-term clinical outcomes of cardiac resynchronization therapy (CRT) in patients with cardiac sarcoidosis.

View Full Paper

Ask AI

Bookmark

Key result

CRT in cardiac sarcoidosis is linked to a ~44 ms QRS reduction but no LVEF improvement.

P<0.001
n=19

Why the study?

The efficacy and outcomes of cardiac resynchronization therapy for cardiac sarcoidosis remain uncertain.

Does cardiac resynchronization therapy improve echocardiographic parameters and clinical outcomes in patients with cardiac sarcoidosis?

Population

19 patients with cardiac sarcoidosis who underwent CRT implantation

Design

Retrospective single-center cohort study

Follow-up

Mean 6.7 ± 4.3 years

Authors

YAYoshiyasu Aizawa KYKenji Yodogawa SOShuhei Okajima

Discussion

Member takes

Overview

CRT in CS yields limited real-world data from small cohorts; leaves open need for prospective trials on efficacy.

Key Points

To assess the efficacy, echocardiographic reverse remodeling, and long-term clinical outcomes of cardiac resynchronization therapy (CRT) in patients with cardiac sarcoidosis.
Retrospective cohort analysis of N=19 patients with cardiac sarcoidosis who underwent CRT implantation (2 CRT-P, 17 CRT-D) between 2007 and 2024 at a single hospital.
Assessed electrical parameters (QRS duration), functional status (NYHA class), and echocardiographic measures (LVEF, LVESV) at 6 months, alongside adverse events over a mean follow-up of 6.7 ± 4.3 years.
At 6 months post-implantation, QRS duration significantly shortened (172 ± 34 vs. 128 ± 27 ms, p < 0.001) and NYHA functional class improved (2.6 ± 0.8 vs. 2.1 ± 1.0, p = 0.037) with a biventricular pacing percentage of 98 ± 2%.
No significant improvement occurred in LVESV (147 ± 74 vs. 155 ± 70 ml, p = 0.878) or LVEF (28 ± 9 vs. 28 ± 11%, p = 0.452).
Long-term follow-up revealed 8 heart failure hospitalizations, 2 appropriate ICD shocks, 6 deaths due to progressive heart failure, and 4 device-related complications.

Study Design

Type

Cohort (n=19)

Multicenter

Structured PICO

Does cardiac resynchronization therapy improve echocardiographic parameters and clinical outcomes in patients with cardiac sarcoidosis?

Population

19 patients with cardiac sarcoidosis undergoing CRT implantation (mean age 70 years, 68% female) followed for a mean of 6.7 years.

Exposure

Cardiac resynchronization therapy (CRT) implantation (2 CRT-Ps and 17 CRT-Ds, including 5 upgrades from pacemakers and 5 from ICDs)

Outcome

Changes in QRS duration, NYHA functional class, left ventricular end-systolic volume (LVESV), and left ventricular ejection fraction (LVEF) at 6 months after device implantationsurrogate

Main Result

Absolute Event Rate: 128% vs 172%

p-value: p=<0.001

In patients with advanced cardiac sarcoidosis, CRT improves QRS duration and NYHA functional class but does not lead to significant echocardiographic reverse remodeling.

Limitations

Small retrospective cohort
Advanced and heterogeneous nature of the underlying disease
Small sample size
Retrospective design

Cite This Study

Aizawa et al. (2026) conducted a cohort in Cardiac sarcoidosis (n=19). Cardiac resynchronization therapy (CRT) vs. Baseline was evaluated on QRS duration at 6 months (p=<0.001). Cardiac resynchronization therapy in cardiac sarcoidosis shortened QRS duration (172 to 128 ms, p<0.001) but did not improve LVEF (28% vs 28%, p=0.452) at 6 months.

synapsesocial.com/papers/6a898307ca7ade938187f3e2 https://doi.org/10.1007/s00380-026-02751-7

View Full Paper

Ask AI

Bookmark

August 22, 2026Heart and Vessels

Real-world clinical outcomes after cardiac resynchronization therapy in cardiac sarcoidosis

View Full Paper

Ask AI

Bookmark

Key result

CRT in cardiac sarcoidosis is linked to a ~44 ms QRS reduction but no LVEF improvement.

P<0.001
n=19

Why the study?

The efficacy and outcomes of cardiac resynchronization therapy for cardiac sarcoidosis remain uncertain.

Does cardiac resynchronization therapy improve echocardiographic parameters and clinical outcomes in patients with cardiac sarcoidosis?

Population

19 patients with cardiac sarcoidosis who underwent CRT implantation

Design

Retrospective single-center cohort study

Follow-up

Mean 6.7 ± 4.3 years

Authors

YAYoshiyasu Aizawa KYKenji Yodogawa SOShuhei Okajima

Discussion

Member takes

Overview

CRT in CS yields limited real-world data from small cohorts; leaves open need for prospective trials on efficacy.

Key Points

To assess the efficacy, echocardiographic reverse remodeling, and long-term clinical outcomes of cardiac resynchronization therapy (CRT) in patients with cardiac sarcoidosis.
Retrospective cohort analysis of N=19 patients with cardiac sarcoidosis who underwent CRT implantation (2 CRT-P, 17 CRT-D) between 2007 and 2024 at a single hospital.
Assessed electrical parameters (QRS duration), functional status (NYHA class), and echocardiographic measures (LVEF, LVESV) at 6 months, alongside adverse events over a mean follow-up of 6.7 ± 4.3 years.
At 6 months post-implantation, QRS duration significantly shortened (172 ± 34 vs. 128 ± 27 ms, p < 0.001) and NYHA functional class improved (2.6 ± 0.8 vs. 2.1 ± 1.0, p = 0.037) with a biventricular pacing percentage of 98 ± 2%.
No significant improvement occurred in LVESV (147 ± 74 vs. 155 ± 70 ml, p = 0.878) or LVEF (28 ± 9 vs. 28 ± 11%, p = 0.452).
Long-term follow-up revealed 8 heart failure hospitalizations, 2 appropriate ICD shocks, 6 deaths due to progressive heart failure, and 4 device-related complications.

Study Design

Type

Cohort (n=19)

Multicenter

Structured PICO

Does cardiac resynchronization therapy improve echocardiographic parameters and clinical outcomes in patients with cardiac sarcoidosis?

Population

19 patients with cardiac sarcoidosis undergoing CRT implantation (mean age 70 years, 68% female) followed for a mean of 6.7 years.

Exposure

Cardiac resynchronization therapy (CRT) implantation (2 CRT-Ps and 17 CRT-Ds, including 5 upgrades from pacemakers and 5 from ICDs)

Outcome

Changes in QRS duration, NYHA functional class, left ventricular end-systolic volume (LVESV), and left ventricular ejection fraction (LVEF) at 6 months after device implantationsurrogate

Main Result

Absolute Event Rate: 128% vs 172%

p-value: p=<0.001

In patients with advanced cardiac sarcoidosis, CRT improves QRS duration and NYHA functional class but does not lead to significant echocardiographic reverse remodeling.

Limitations

Small retrospective cohort
Advanced and heterogeneous nature of the underlying disease
Small sample size
Retrospective design

Cite This Study

synapsesocial.com/papers/6a898307ca7ade938187f3e2 https://doi.org/10.1007/s00380-026-02751-7

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark